First-generation CAR-T cells targeting PSMA were constructed with a chimeric anti-PSMA immunoglobulin-T-cell receptor gene based on the monoclonal antibody 3D8.323 Second-generation CAR-T cells were constructed by inserting the CD28 signal domain into first-generation CAR-T cells.324 Recently, many new PSMA-based CAR-T cells, such as CART-PSMA-TGFβRDN, have been evaluated in phase 1 clinical trials in CRPC patients.42 Meanwhile, other clinical trials are underway and will test the safety and efficacy of PSMA-targeted CAR-T cells for the treatment of PCa (Table 4). This evidence concerns the gene FOLH1 and posterior cortical atrophy.